Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age19+
SponsorYOUNGIL KOH
About this trial
The goal of this clinical trial is to find out how well a combination of two medicines (mezigdomide and elranatamab) works in treating patients with refractory/relapsed multiple myeloma.
Eligibility criteria
Qualifiers
Subject is ≥ 19 years of age at the time of signing the informed consent form (ICF).
Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
Subject must have documented disease progression during or after their last antimyeloma regimen.
True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, post-ovulation methods) and withdrawal are not acceptable methods of contraception].
Disqualifiers
1 Subject who has had prior treatment with mezigdomide. 2 Patients with gastrointestinal disease or surgery (eg, gastric bypass surgery) that may significantly alter the absorption of mezigdomide and/or other oral study intervention.
Trial design
Treatments tested in this trial
- Elranatamab
- Mezigdomide
- Dexamethasone
Treatment groups
75 Participants
are divided into 1 treatment groupSponsors and collaborators
YOUNGIL KOH
Lead sponsor
Seoul National University Hospital
Sponsor institution
Source ClinicalTrials.gov